The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design

BACKGROUND: Randomized controlled trials showed the nonvitamin K oral anticoagulant (NOAC) edoxaban was effective and safe for stroke and systemic embolism prevention in nonvalvular atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolism (VTE; including pulmonary embo...

Descripción completa

Detalles Bibliográficos
Autores principales: De Caterina, Raffaele, Agnelli, Giancarlo, Laeis, Petra, Unverdorben, Martin, Rauer, Heiko, Wang, Chun‐Chieh, Nakamura, Mashio, Chiu, Kuan‐Ming, Reimitz, Paul‐Egbert, Koretsune, Yukihiro, Chen, Cathy, Thee, Ulrike, Kaburagi, Jumpei, Kim, Young‐Hoon, Choi, Won‐Il, Yamashita, Takeshi, Cohen, Alexander, Kirchhof, Paulus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2019
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906985/
https://www.ncbi.nlm.nih.gov/pubmed/31650560
http://dx.doi.org/10.1002/clc.23279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906985/
https://www.ncbi.nlm.nih.gov/pubmed/31650560
http://dx.doi.org/10.1002/clc.23279

Ejemplares similares